Association of iRhom1 and iRhom2 expression with prognosis in patients with cervical cancer and possible signaling pathways

Xu,Qin; Chen,Chuanben; Liu,Bin; Lin,Yibin; Zheng,Peng; Zhou,Dongmei; Xie,Yunqing; Lin,Ya; Guo,Ciren; Liu,Jing; Li,Li

doi:10.3892/or.2019.7389

Association of iRhom1 and iRhom2 expression with prognosis in patients with cervical cancer and possible signaling pathways

Authors:
- Qin Xu
- Chuanben Chen
- Bin Liu
- Yibin Lin
- Peng Zheng
- Dongmei Zhou
- Yunqing Xie
- Ya Lin
- Ciren Guo
- Jing Liu
- Li Li
View Affiliations

Affiliations: Department of Gynecology, Fujian Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China, Department of Oncology, Fujian Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China, Department of Research Pathology, Fujian Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China, Department of Research Center, Fujian Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China
Published online on: October 25, 2019 https://doi.org/10.3892/or.2019.7389
Pages: 41-54
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several proteins in the iRhom family function as oncogenic regulators in certain cancers. However, the function of these proteins in cervical cancer (CC) is unknown. The relationship of iRhom1 and iRhom2 expression with the clinicopathological features and prognosis of patients with CC was investigated, and their possible molecular mechanisms were examined using in vitro experiments. The expression of iRhom1 and iRhom2 in CC samples of 83 patients was determined by immunohistochemistry (IHC), and the associations of their expression with the clinicopathological features of patients were determined. The relationship of iRhom1, iRhom2, and Ki‑67 expression with survival rates was determined using Kaplan‑Meier analysis and Cox regression analyses. HeLa cells were analyzed using MTT assays, cell cycle analysis, and apoptosis assays. The results revealed that CC tissues had higher levels of iRhom1 and iRhom2 than adjacent normal tissues. Increased expression of iRhom1, iRhom2, and K‑i67 was significantly associated with tumor stage, size, and parametrium invasion. High expression of iRhom1, iRhom2 and Ki‑67 was correlated with poor outcomes. Cancer stage and iRhom2 expression were independent prognostic indicators of CC. Knockdown of iRhom1 and iRhom2 in HeLa cells inhibited cell proliferation, promoted the G1 phase and relieved S‑phase arrest, and induced apoptosis. Genomic microarray analysis indicated that iRhom2 knockdown altered several pathways with roles in oncogenesis, including the expression of five genes in the Wnt/β‑catenin pathway. Western blotting in HeLa cells revealed that iRhom1 knockdown significantly suppressed the expression of β‑catenin, Myc, p‑EGFR and TGFBR2, and increased the expression of FAS; iRhom2 knockdown significantly suppressed the expression of β‑catenin, GSK3β, p‑EGFR and Myc. These results were consistent with the genomic microarray data. Collectively, the results indicated that iRhom1 and iRhom2 may function as oncogenes in CC and are potential therapeutic targets.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
2	Kim SW, Chun M, Ryu HS, Chang SJ, Kong TW, Lee EJ, Lee YH and Oh YT: Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer. Strahlenther Onkol. 193:534–542. 2017. View Article : Google Scholar : PubMed/NCBI
3	Munro A, Codde J, Spilsbury K, Steel N, Stewart CJ, Salfinger SG, Tan J, Mohan GR, Leung Y, Semmens JB, et al: Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. Am J Obstet Gynecol. 216:272.e1–272.e7. 2017. View Article : Google Scholar
4	Sturtevant MA, Roark M and Bier E: The Drosophila rhomboid gene mediates the localized formation of wing veins and interacts genetically with components of the EGF-R signaling pathway. Genes Dev. 7:961–973. 1993. View Article : Google Scholar : PubMed/NCBI
5	Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A and Li LY: Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J. 23:425–432. 2009. View Article : Google Scholar : PubMed/NCBI
6	Li J, Bai TR, Gao S, Zhou Z, Peng XM, Zhang LS, Dou DL, Zhang ZS and Li LY: Human rhomboid family-1 modulates clathrin coated vesicle-dependent pro-transforming growth factor α membrane trafficking to promote breast cancer progression. Ebiomedicine. 36:229–240. 2018. View Article : Google Scholar : PubMed/NCBI
7	Yuan H, Wei R, Xiao Y, Song Y, Wang J, Yu H, Fang T, Xu W and Mao S: RHBDF1 regulates APC-mediated stimulation of the epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells in part via the Wnt/β-catenin signalling pathway. Exp Cell Res. 368:24–36. 2018. View Article : Google Scholar : PubMed/NCBI
8	Adrain C, Zettl M, Christova Y, Taylor N and Freeman M: Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 335:225–228. 2012. View Article : Google Scholar : PubMed/NCBI
9	McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, et al: iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 335:229–232. 2012. View Article : Google Scholar : PubMed/NCBI
10	Blaydon DC, Etheridge SL, Risk JM, Hennies HC, Gay LJ, Carroll R, Plagnol V, McRonald FE, Stevens HP, Spurr NK, et al: RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet. 90:340–346. 2012. View Article : Google Scholar : PubMed/NCBI
11	Xu Q, Ying M, Chen G, Lin A, Xie Y, Ohara N and Zhou D: ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma. Tumour Biol. 35:7575–7586. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zettl M, Adrain C, Strisovsky K, Lastun V and Freeman M: Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling. Cell. 145:79–91. 2011. View Article : Google Scholar : PubMed/NCBI
13	Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY and Li LY: Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther. 7:1355–1364. 2008. View Article : Google Scholar : PubMed/NCBI
14	Arcidiacono P, Webb CM, Brooke MA, Zhou H, Delaney PJ, Ng KE, Blaydon DC, Tinker A, Kelsell DP and Chikh A: p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response. Nat Commun. 9:10212018. View Article : Google Scholar : PubMed/NCBI
15	Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, Lin SJ, Kalpana R, Tay ST, Suzuki Y, et al: Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells. Gastroenterology. 153:191–204.e16. 2017. View Article : Google Scholar : PubMed/NCBI
16	Wojnarowicz PM, Provencher DM, Mes-Masson AM and Tonin PN: Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol. 40:1865–1880. 2012.PubMed/NCBI
17	Li X, Maretzky T, Weskamp G, Monette S, Qing X, Issuree PD, Crawford HC, McIlwain DR, Mak TW, Salmon JE and Blobel CP: iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc Natl Acad Sci USA. 112:6080–6085. 2015. View Article : Google Scholar : PubMed/NCBI
18	Etheridge SL, Brooke MA, Kelsell DP and Blaydon DC: Rhomboid proteins: A role in keratinocyte proliferation and cancer. Tissue Cell Res. 351:301–307. 2013. View Article : Google Scholar
19	Zhang Y, Li Y, Yang X, Wang J, Wang R, Qian X, Zhang W and Xiao W: Uev1A-Ubc13 catalyzes K63-linked ubiquitination of RHBDF2 to promote TACE maturation. Cell Signal. 42:155–164. 2018. View Article : Google Scholar : PubMed/NCBI
20	Hosur V, Johnson KR, Burzenski LM, Stearns TM, Maser RS and Shultz LD: Rhbdf2 mutations increase its protein stability and drive EGFR hyperactivation through enhanced secretion of amphiregulin. Proc Natl Acad Sci USA. 111:E2200–E2209. 2014. View Article : Google Scholar : PubMed/NCBI
21	Siggs OM, Grieve A, Xu H, Bambrough P, Christova Y and Freeman M: Genetic interaction implicates iRhom2 in the regulation of EGF receptor signalling in mice. Biol Open. 3:1151–1157. 2014. View Article : Google Scholar : PubMed/NCBI
22	Vembar SS and Brodsky JL: One step at a time: Endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol. 9:944–957. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wang R, Li Y, Tsung A, Huang H, Du Q, Yang M, Deng M, Xiong S, Wang X, Zhang L, et al: iNOS promotes CD24⁺CD133⁺ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway. Proc Natl Acad Sci USA. 115:E10127–E10136. 2018. View Article : Google Scholar : PubMed/NCBI
24	Cataisson C, Michalowski AM, Shibuya K, Ryscavage A, Klosterman M, Wright L, Dubois W, Liu F, Zhuang A, Rodrigues KB, et al: MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis. Sci Signal. 9:ra622016. View Article : Google Scholar : PubMed/NCBI
25	Nusse R and Clevers H: Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
26	Gonzalez DM and Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 7:re82014. View Article : Google Scholar : PubMed/NCBI
27	McCrea PD and Gottardi CJ: Beyond β-catenin: Prospects for a larger catenin network in the nucleus. Nat Rev Mol Cell Biol. 17:55–64. 2016. View Article : Google Scholar : PubMed/NCBI
28	Stamos JL and Weis WI: The β-catenin destruction complex. Cold Spring Harb Perspect Biol. 5:a0078982013. View Article : Google Scholar : PubMed/NCBI
29	Ueda T, Tsubamoto H, Inoue K, Sakata K, Shibahara H and Sonoda T: Itraconazole modulates hedgehog, WNT/β-catenin, as well as Akt signalling, and inhibits proliferation of cervical cancer cells. Anticancer Res. 37:3521–3526. 2017.PubMed/NCBI
30	Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F and Jablons DM: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64:4717–4720. 2004. View Article : Google Scholar : PubMed/NCBI
31	Takigawa Y and Brown AM: Wnt signaling in liver cancer. Curr Drug Targets. 9:1013–1024. 2008. View Article : Google Scholar : PubMed/NCBI
32	Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
33	Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 101:3118–3123. 2004. View Article : Google Scholar : PubMed/NCBI
34	Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Liu HS, Chu DW and Lin YW: SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol. 112:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
35	Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC and Yu MH: Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol. 135:1665–1674. 2009. View Article : Google Scholar : PubMed/NCBI
36	Lee J, Yoon YS and Chung JH: Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines. Gynecol Oncol. 109:270–274. 2008. View Article : Google Scholar : PubMed/NCBI
37	Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R and Üren A: Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. PLoS One. 6:e272432011. View Article : Google Scholar : PubMed/NCBI
38	Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S and Queimado L: Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 31:2725–2737. 2012. View Article : Google Scholar : PubMed/NCBI
39	Liu XF, Li XY, Zheng PS and Yang WT: DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β. Cell Death Dis. 9:3392018. View Article : Google Scholar : PubMed/NCBI
40	Perez-Yepez EA, Ayala-Sumuano JT, Lezama R and Meza I: A novel β-catenin signaling pathway activated by IL-1β leads to the onset of epithelial-mesenchymal transition in breast cancer cells. Cancer Lett. 354:164–171. 2014. View Article : Google Scholar : PubMed/NCBI